Gain Therapeutics, Inc.

GAIN Therapeutics, Inc. is a biotechnology company focused on developing novel small molecule therapeutics for diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and oncology, by targeting protein degradation. The company utilizes its proprietary computational target and drug discovery platform, Magellan™, to identify novel allosteric binding sites on disease-implicated proteins and subsequently identify small molecules, referred to as Structurally Targeted Allosteric Regulators (STARs), that modulate protein function to treat the underlying cause of disease. The Magellan™ platform is designed to identify allosteric binding sites, which offer advantages such as regulating proteins through various mechanisms (stabilization, destabilization, targeted degradation, allosteric inhibition, and activation), improved specificity due to non-competitive binding, and the potential for small molecules with more favorable drug-like properties, including the ability to cross the blood-brain barrier ¹.

The core business model revolves around the discovery and development of STARs using the Magellan™ platform. The company aims to generate revenue through the successful completion of preclinical and clinical development, obtaining regulatory approvals, and then commercializing its product candidates, potentially through third-party partnerships. Primary customer segments, once products are approved, would be patients suffering from the targeted diseases, such as Parkinson's disease and Gaucher disease. The company's revenue generation is currently limited, as it has not generated any revenue from product sales to date ².

The company's lead product candidate, GT-02287, is in clinical development for the treatment of Parkinson's disease, both with and without GBA1 mutations. Preclinical data for GT-02287 demonstrated its ability to restore glucocerebrosidase (GCase) function, improve mitochondrial health, reduce toxic lipid substrates and alpha-synuclein, decrease neuroinflammation, enhance dopaminergic neuron survival, increase dopamine levels, restore locomotor function and cognition, and reduce neurofilament light chain (NfL) levels in preclinical models of Parkinson's disease ³. GT-02287 has completed a first-in-human Phase 1 clinical trial in Australia involving 72 healthy volunteers, showing safety and tolerability up to the highest planned dose levels, linear pharmacokinetic profile, CNS exposure, and a 53% increase in mean GCase activity in dried blood spots at the highest dose ⁴. A Phase 1 relative bioavailability study comparing two oral formulations of GT-02287 in healthy volunteers was completed in the third quarter of 2025 ⁵. An ongoing two-part Phase 1b safety and tolerability study for GT-02287 in 15-20 Parkinson's disease patients (with or without GBA1 mutation) completed Part 1 in November 2025, with 19 patients completing this part and 16 electing to continue into the optional 9-month Part 2, expected to be completed in September 2026 ⁶.

For the fiscal year ended December 31, 2025, GAIN Therapeutics reported a net loss of $20,161,099 ⁷, an improvement from a net loss of $20,411,191 ⁸ in the prior year. Basic and diluted net loss per share attributable to common stockholders was $(0.61) ⁹ for 2025, compared to $(0.89) ¹⁰ for 2024. Total operating expenses decreased to $(18,710,702) ¹¹ in 2025 from $(20,350,592) ¹² in 2024. The company's cash and cash equivalents stood at $20,837,628 ¹³ as of December 31, 2025, up from $10,385,863 ¹⁴ at December 31, 2024. The accumulated deficit increased to $101,356,007 ¹⁵ as of December 31, 2025, from $81,194,908 ¹⁶ as of December 31, 2024. Total liabilities were $4,254,227 ¹⁷ and total stockholders' equity was $18,564,748 ¹⁸ as of December 31, 2025. The company had indebtedness of $400,953 ¹⁹ as of December 31, 2025.

Year-over-year, research and development expenses decreased by $578,276 ²⁰ to $10,212,782 ²¹ in 2025 from $10,791,058 ²² in 2024, primarily due to pipeline cost optimization, partially offset by unfavorable foreign exchange currency translation. General and administrative expenses decreased by $1,061,614 ²³ to $8,497,920 ²⁴ in 2025 from $9,559,534 ²⁵ in 2024, mainly due to lower stock-based compensation and legal fees, partially offset by higher personnel costs and unfavorable foreign exchange translation. Interest income, net, decreased by $112,702 ²⁶ to $244,394 ²⁷ in 2025 from $357,096 ²⁸ in 2024, attributed to lower interest income from maturing treasury securities and a reduced money market fund balance. Foreign exchange loss, net, increased by $952,793 ²⁹ to a loss of $833,673 ³⁰ in 2025 from a gain of $119,120 ³¹ in 2024, due to the strengthening Swiss franc against the U.S. dollar. Income taxes increased by $324,303 ³² to $861,118 ³³ in 2025 from $536,815 ³⁴ in 2024, mainly due to higher income taxes payable in Australia.

During 2025, the company completed a public offering in July, issuing 4,501,640 shares of common stock and warrants to purchase 2,250,820 shares, generating gross proceeds of $7.0 million ³⁵ and net proceeds of $6.0 million ³⁶. The underwriter also exercised an over-allotment option for an additional 675,246 shares and warrants for 337,623 shares, yielding $1.1 million ³⁷ in gross proceeds and $1.0 million ³⁸ in net proceeds. Warrants to purchase 362,382 shares were issued to the underwriter ³⁹. Additionally, 1,146,821 public warrants were exercised, resulting in $1.9 million ⁴⁰ in net proceeds. The company also sold 6,850,679 shares of common stock under its 2024 ATM Program at an average price of $2.74 per share, raising gross proceeds of $18.8 million ⁴¹ and net proceeds of $18.1 million ⁴². In December 2025, 482,290 investor warrants and 240,652 placement agent warrants from 2023 offerings were exercised, generating $1.3 million ⁴³ in net proceeds. However, 225,387 warrants issued in 2020 and 200,000 warrants issued in 2021 were forfeited due to non-exercise within their respective exercisable periods ⁴⁴.

GAIN Therapeutics expects to continue incurring operating losses for the foreseeable future and has not generated any revenue from product sales to date, nor does it anticipate doing so in the near term ⁴⁵. The company's current operating plan indicates that its existing cash and cash equivalents of $20.8 million ⁴⁶ as of December 31, 2025, will be sufficient to fund anticipated operating and capital requirements only into the first quarter of 2027 ⁴⁷. This raises substantial doubt about the company's ability to continue as a going concern beyond this period, necessitating additional capital ⁴⁸.

The primary growth area for GAIN Therapeutics is the advancement of its lead clinical candidate, GT-02287, for Parkinson's disease. The company is currently preparing to initiate Phase 2 clinical testing for GT-02287 during the third quarter of 2026 ⁴⁹. This follows the completion of Part 1 of the Phase 1b study in November 2025, with 16 out of 19 patients electing to continue into the optional 9-month Part 2, which is expected to be completed in September 2026 ⁵⁰. The company plans to present the full analysis of Part 1 throughout 2026 ⁵¹. The favorable safety, tolerability, CNS exposure, and target engagement demonstrated in earlier Phase 1 studies strengthen GT-02287's potential as a treatment for Parkinson's disease in patients with or without a GBA1 mutation ⁵².

Beyond GT-02287, the company plans to continue advancing its existing research programs and initiate additional programs targeting allosteric binding sites identified with the Magellan™ platform in various therapeutic areas. These efforts will be pursued through academic partnerships, co-development, and licensing arrangements ⁵³. The Magellan™ platform's disease-agnostic nature provides the ability to expand the pipeline quickly, efficiently, and at low cost ⁵⁴.

The company anticipates that its research and development expenses will increase substantially in future periods to support progress in its research and development activities, including the progression of clinical trials for product candidates. These increases are also expected to result from expanded infrastructure and increased insurance costs ⁵⁵. General and administrative expenses are also a focus for optimization, with management actively reviewing the cost structure throughout the organization to improve the overall cash burn rate and reduce these expenses ⁵⁶.

GAIN Therapeutics expects to finance its cash needs through a combination of public and private equity offerings, including at-the-market offerings, debt financings, government or private party grants, collaborations, strategic alliances, and licensing arrangements ⁵⁷. As of December 31, 2025, the company had $28 million ⁵⁸ of common stock remaining available for sale under its 2024 ATM Program. The company does not currently maintain any lines of credit or equity capital committed for funding, with the exception of the 2024 ATM Program ⁵⁹.

GAIN Therapeutics faces substantial risks, including significant doubt about its ability to continue as a going concern, given its history of operating losses and expectation to incur further losses, with current cash and cash equivalents of $20.8 million ⁶⁰ only sufficient into the first quarter of 2027 ⁶¹. The company will require additional financing, which may not be available on acceptable terms or at all, potentially forcing delays or elimination of research and development programs. Regulatory risks are extensive and costly, with the lengthy and uncertain approval process for product candidates, and the possibility of clinical trial delays or failures, particularly given the low prevalence of some target disorders which can hinder patient enrollment. The company's reliance on a license from Minoryx Therapeutics S.L. for its Magellan™ platform and related intellectual property is a material risk, as termination of this agreement would halt its ability to market certain products and technology. Furthermore, the company faces intense competition from larger pharmaceutical and biotechnology companies with greater resources, and its novel therapeutic approach may not lead to marketable products. Global and macroeconomic conditions, including political instability, natural disasters, wars (such as the war in Ukraine and the recent conflict in Iran and the Middle East), and trade tensions (particularly with China, where a third-party manufacturer is located), could adversely affect operations, supply chains, and financial performance. The company is also subject to stringent and evolving data privacy and security laws, including the EU GDPR, UK GDPR, and CCPA, with potential for significant fines (up to 20 million euros under EU GDPR or 4% of annual global revenue ⁶²) and litigation for non-compliance, and risks associated with the use of generative AI technologies. Product liability lawsuits pose an inherent risk, with current limited insurance coverage, and an adverse outcome could exceed total assets.

Management's message to shareholders emphasizes the company's focus as a biotechnology company developing novel small molecule therapeutics across CNS disorders, lysosomal storage disorders, metabolic disorders, and oncology, leveraging its proprietary Magellan™ platform. A key strategic priority is the advancement of its lead clinical candidate, GT-02287, for Parkinson's disease, with the company preparing to initiate Phase 2 clinical testing during the third quarter of 2026 ⁶³. Management also highlights the ongoing efforts to advance existing research programs and initiate additional programs through academic partnerships, co-development, and licensing arrangements, utilizing the Magellan™ platform's disease-agnostic capabilities. A critical theme is the need for additional financing, as current cash and cash equivalents of $20.8 million ⁶⁴ are projected to fund operations only into the first quarter of 2027 ⁶⁵, leading to substantial doubt about the company's ability to continue as a going concern. Management plans to address this by raising additional capital through equity and/or debt financings and actively seeking strategic collaborations, licensing agreements, and grant funding, while also reviewing the cost structure to optimize expenditures and improve the cash burn rate.